EUVIMEDEUVIMED entdecken
Querschnittstudie

Lipid-lowering therapy disparities between peripheral artery disease and cardiocerebrovascular disease in type 2 diabetes: A multicenter cross-sectional study

Xiao-Qi Ye, Yan Li, Bing-Xue Wang, Li-Hong Chen, Ai-Hong Wang, Zhang-Rong Xu, Li-Nong Ji, Xing-Wu Ran

World Journal of Diabetes · 16.11.2026

DOI: 10.4239/wjd.126228 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift World Journal of Diabetes, online erschienen am 16.11.2026. Verfasst von Xiao-Qi Ye und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Peripheral artery disease (PAD) is an important manifestation of systemic atherosclerotic cardiovascular disease (ASCVD).However, whether lipid management differs between individuals with PAD and those with cardiocerebrovascular disease (CVD), a term used here for coronary artery disease or cerebrovascular disease, among adults with type 2 diabetes in China remains unclear.AIM To assess disparities in lipid-lowering therapy between PAD and CVD among adults with type 2 diabetes at elevated ASCVD risk in a multicenter, hospital-based, crosssectional study in China.METHODS This study used China DIA-LEAD data collected from June 2016 to January 2017 across 30 hospitals.Adults aged 50 years or older with type 2 diabetes and complete lipid data were included.ASCVD status was classified as no ASCVD, PAD only, CVD only, or PAD + CVD.PAD was defined as ankle-brachial index ≤ 0.90 or physician-diagnosed PAD; CVD as physician-diagnosed coronary artery disease or cerebrovascular disease.Logistic regression estimated odds of therapy, adjusted for demographic and cardiometabolic covariates.RESULTS Among 8941 participants, 54.1% were female, and median age was 63.0 years.Dyslipidemia prevalence was 75.2%, and 48.2% of participants received lipid-lowering therapy.Among treated individuals, only 14.6% achieved low-density lipoprotein cholesterol control.Compared with no ASCVD, CVD only was associated with higher 4 / 41 treatment odds [adjusted odds ratio (OR), 1.49; 95%CI: 1.32-1.68],whereas PAD only was not (adjusted OR, 0.99; 95%CI: 0.85-1.14).Among participants with PAD only or CVD only, PAD only was associated with lower treatment odds (adjusted OR, 0.67; 95%CI: 0.56-0.79).CONCLUSION PAD only was associated with less frequent lipid-lowering therapy than CVD only, suggesting that PAD should trigger the same systematic lipid-management attention as other ASCVD manifestations in diabetes care.Key limitations include the crosssectional design and residual confounding from unmeasured factors.Strategies to improve PAD detection and lipid management require prospective evaluation.

Zitieren

APA

Ye, X., Li, Y., Wang, B., Chen, L., Wang, A., Xu, Z., Ji, L., & Ran, X. (2026). Lipid-lowering therapy disparities between peripheral artery disease and cardiocerebrovascular disease in type 2 diabetes: A multicenter cross-sectional study. World Journal of Diabetes. https://doi.org/10.4239/wjd.126228

Vancouver

Ye X, Li Y, Wang B, Chen L, Wang A, Xu Z, et al. Lipid-lowering therapy disparities between peripheral artery disease and cardiocerebrovascular disease in type 2 diabetes: A multicenter cross-sectional study. World Journal of Diabetes. 2026. doi:10.4239/wjd.126228

BibTeX
@article{Ye2026,
  author = {Ye, Xiao-Qi and Li, Yan and Wang, Bing-Xue and Chen, Li-Hong and Wang, Ai-Hong and Xu, Zhang-Rong and Ji, Li-Nong and Ran, Xing-Wu},
  title = {Lipid-lowering therapy disparities between peripheral artery disease and cardiocerebrovascular disease in type 2 diabetes: A multicenter cross-sectional study},
  journal = {World Journal of Diabetes},
  year = {2026},
  doi = {10.4239/wjd.126228}
}
Kostenlos starten →